Home Newsletters Prostate Cell News LAVA Therapeutics Announces Treatment of First Patient in Phase I/IIa Clinical Trial...

LAVA Therapeutics Announces Treatment of First Patient in Phase I/IIa Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer

By
Justin.choi
-
0
LAVA Therapeutics announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-1207 in patients with metastatic CRPC.
[LAVA Therapeutics]

Sorry, but the selected Zotpress account can't be found.

Press Release

RELATED ARTICLES

Exit mobile version